e10vq

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q


þ		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED June 30, 2006


o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NUMBER: 0-13976

AKORN, INC.

(Exact Name of Registrant as Specified in its Charter)


LOUISIANA		72-0717400
(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation or Organization)		Identification No.)

2500 MILLBROOK DRIVE
BUFFALO GROVE, ILLINOIS		60089
(Address of Principal Executive Offices)		(Zip Code)

(847) 279-6100

(Registrant’s telephone number)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ No o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Exchange Act Rule 12b-2).

Large accelerated filer o Accelerated filer o Non-accelerated filer þ

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2).

Yes o No þ

At July 31, 2006 there were 75,336,572 shares of common stock, no par value, outstanding.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

AKORN, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
IN THOUSANDS


	JUNE 30,			DECEMBER 31,
	2006			2005
	(UNAUDITED)			(AUDITED)
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	17,781		$	791
Trade accounts receivable (less allowance for doubtful accounts of $3 and $13, respectively)		4,987			3,222
Inventories		10,970			10,279
Prepaid expenses and other current assets		1,780			1,402

TOTAL CURRENT ASSETS		35,518			15,694
PROPERTY, PLANT AND EQUIPMENT, NET		31,515			31,071
OTHER LONG-TERM ASSETS
Intangibles, net		9,509			10,210
Other		105			120

TOTAL OTHER LONG-TERM ASSETS		9,614			10,330

TOTAL ASSETS	$	76,647		$	57,095

LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES
Current installments of debt	$	380		$	7,044
Trade accounts payable		2,732			3,046
Accrued compensation		1,168			1,519
Customer accrued liabilities		332			135
Accrued interest payable		—			2,514
Accrued expenses and other liabilities		730			1,202

TOTAL CURRENT LIABILITIES		5,342			15,460
LONG-TERM LIABILITIES
Long-term debt, less current installments		408			602
Product warranty		1,159			—

TOTAL LONG-TERM LIABILITIES		1,567			602

TOTAL LIABILITIES		6,909			16,062

SHAREHOLDERS’ EQUITY
Common stock, no par value — 150,000,000 shares authorized; 75,285,018 and 27,618,745 shares issued and outstanding at June 30, 2006 and December 31, 2005, respectively		124,907			67,339
Series A Preferred Stock, $1.00 par value, 257,172 shares authorized and issued, 241,122 shares outstanding at December 31, 2005		—			27,232
Series B Preferred Stock, $1.00 par value, 170,000 shares authorized, 141,000 shares issued, 82,437 outstanding at June 30, 2006 and 106,600 outstanding at December 31, 2005		8,589			10,758
Warrants to acquire common stock		13,631			13,696
Accumulated deficit		(77,389	)		(77,992	)

TOTAL SHAREHOLDERS’ EQUITY		69,738			41,033

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	76,647		$	57,095

See notes to condensed consolidated financial statements.

AKORN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
IN THOUSANDS, EXCEPT PER SHARE DATA
(UNAUDITED)


	THREE MONTHS ENDED						SIX MONTHS ENDED
	JUNE 30,						JUNE 30,
	2006			2005			2006			2005
Revenues	$	12,475		$	12,578		$	42,205		$	22,759
Cost of sales		7,520			7,726			25,517			14,564

GROSS PROFIT		4,955			4,852			16,688			8,195
Selling, general and administrative expenses		4,669			3,699			9,153			7,067
Amortization and write-down of intangibles		350			425			701			804
Research and development expenses		2,121			1,423			4,166			2,765

TOTAL OPERATING EXPENSES		7,140			5,547			14,020			10,636

OPERATING INCOME (LOSS)		(2,185	)		(695	)		2,668			(2,441	)
Interest income/(expense) — net		234			(584	)		(1,085	)		(1,110	)
Debt Retirement Gain/(Expense)		—			1,212			(391	)		1,212
Other Expense		(12	)		—			(29	)		—

INCOME/(LOSS) BEFORE INCOME TAXES		(1,963	)		(67	)		1,163			(2,339	)
Income tax provision		—			—			—			15

NET INCOME/(LOSS)		(1,963	)		(67	)		1,163			(2,354	)
Preferred stock dividends and adjustments		(234	)		(915	)		(560	)		(1,976	)

NET INCOME/(LOSS) AVAILABLE TO COMMON STOCKHOLDERS	$	(2,197	)	$	(982	)	$	603		$	(4,330	)

NET INCOME/(LOSS) PER SHARE:
BASIC	$	(0.03	)	$	(0.04	)	$	0.01		$	(0.17	)

DILUTED	$	(0.03	)	$	(0.04	)	$	0.01		$	(0.17	)

SHARES USED IN COMPUTING NET INCOME/(LOSS) PER SHARE:
BASIC		74,853			25,961			68,321			25,601

DILUTED		74,853			25,961			76,481			25,601

See notes to condensed consolidated financial statements.

AKORN, INC.
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY
FOR THE SIX MONTHS ENDED JUNE 30, 2006 AND 2005
UNAUDITED
(In Thousands)


											Warrants to
					Series A			Series B			acquire			Retained Earnings
	Common Stock				Preferred			Preferred			Common			(Accumulated
Six Months Ended June 30, 2006	Shares		Amount		Stock			Stock			Stock			Deficit)			Total
BALANCES AT DECEMBER 31, 2005		27,619	$	67,339	$	27,232		$	10,758		$	13,696		$	(77,992	)	$	41,033
Net income		—		—		—			—			—			1,163			1,163
Preferred stock dividends earned		—		—		55			302			—			(357	)		—
Intrinsic value of beneficial conversion features in convertible preferred stock		—		203		—			—			—			(203	)		—
Conversion of preferred stock into common stock		37,779		29,758		(27,287	)		(2,471	)		—			—			—
Exercise of warrants into common stock		1,413		2,774		—			—			(1,886	)		—			888
Conversion of convertible notes into common stock		3,540		7,298		—			—			—			—			7,298
Net proceeds from issuance of common stock and warrants		4,312		16,257		—			—			1,821			—			18,078
Stock issuance under stock option and stock purchase plans		622		300		—			—			—			—			300
Amortization of deferred compensation related to restricted stock awards		—		277		—			—			—			—			277
FAS123R share based payment expense		—		701		—			—			—			—			701


BALANCES AT JUNE 30, 2006		75,285	$	124,907	$	—		$	8,589		$	13,631		$	(77,389	)	$	69,738


										Warrants to
					Series A		Series B			acquire			Retained Earnings
	Common Stock				Preferred		Preferred			Common			(Accumulated
Six Months Ended June 30, 2005	Shares		Amount		Stock		Stock			Stock			Deficit)			Total
BALANCES AT DECEMBER 31, 2004		25,133	$	59,571	$	25,787	$	13,109		$	14,160		$	(65,301	)	$	47,326
Net loss		—		—		—		—			—			(2,354	)		(2,354	)
Preferred stock dividends earned		—		—		752		405			—			(1,157	)		—
Intrinsic value of beneficial conversion features in convertible preferred stock		—		819		—		—			—			(819	)		—
Conversion of preferred stock into common stock		576		1,443		—		(1,443	)		—			—			—
Exercise of warrants into common stock		50		101		—		—			(64	)		—			37
Intrinsic value of beneficial conversion features in convertible interest		—		134		—		—			—			—			134
Stock issuance under stock option and stock purchase plans		250		444		—		—			—			—			444
Amortization of deferred compensation related to restricted stock awards		—		150		—		—			—			—			150

BALANCES AT JUNE 30, 2005		26,009	$	62,662	$	26,539	$	12,071		$	14,096		$	(69,631	)	$	45,737

See notes to the condensed consolidated financial statements.

AKORN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
IN THOUSANDS
(UNAUDITED)


	SIX MONTHS
	ENDED JUNE 30
	2006			2005
OPERATING ACTIVITIES
Net income (loss)	$	1,163		$	(2,354	)
Adjustments to reconcile net income/(loss) to net cash provided by (used in) operating activities:
Depreciation and amortization		1,645			3,413
Amortization of debt discounts		1,059			553
Advances to Strides Arcolab Limited		—			(1,500	)
Gain on Retirement of Debt		—			(1,212	)
Non-cash stock compensation expense		978			150
Changes in operating assets and liabilities:
Trade accounts receivable		(1,765	)		849
Inventories		(691	)		(227	)
Prepaid expenses and other current assets		(363	)		365
Trade accounts payable		(314	)		(2,382	)
Product warranty		1,159			—
Accrued customer liability		197			—
Accrued expenses and other liabilities		(1,039	)		227

NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES		2,029			(2,118	)
INVESTING ACTIVITIES
Purchases of property, plant and equipment		(1,388	)		(357	)
Purchase of intangible assets		—			(75	)

NET CASH USED IN INVESTING ACTIVITIES		(1,388	)		(432	)
FINANCING ACTIVITIES (See Note 1 below)
Repayment of long-term debt		(2,917	)		(167	)
Repayment of NeoPharm Debt		—			(2,500	)
Net borrowings under lines of credit		—			663
Proceeds from common stock and warrant offering		18,078			—
Proceeds from warrants exercised		888			37
Proceeds under stock option and stock purchase plans		300			444

NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES		16,349			(1,523	)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		16,990			(4,073	)
Cash and cash equivalents at beginning of period		791			4,110

CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	17,781		$	37

Amount paid for interest	$	561		$	365
Amount paid for income taxes	$	2		$	72

See notes to condensed consolidated financial statements.


Note 1:		In March 2006, $7,298 in principal and interest related to convertible notes was retired by conversion to the common stock of Akorn, Inc. (See Note H – Financing Arrangements)

AKORN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

NOTE A — BUSINESS AND BASIS OF PRESENTATION

Business: Akorn, Inc. and its wholly owned subsidiary, Akorn (New Jersey), Inc. (collectively, the “Company”) manufacture and market diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. Customers, including physicians, optometrists, wholesalers, group purchasing organizations and other pharmaceutical companies, are served primarily from three operating facilities in the United States. In September 2004, the Company, along with a venture partner, Strides Arcolab Limited (“Strides”) formed a mutually owned limited liability company, Akorn-Strides, LLC (the “Joint Venture Company”). The accompanying unaudited condensed consolidated financial statements include the accounts of Akorn, Inc. and Akorn (New Jersey) Inc. as well as the accounts and results of the Joint Venture Company. Intercompany transactions and balances have been eliminated in consolidation.

Basis of Presentation: These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and accordingly do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included in these financial statements. Operating results for the six-month period ended June 30, 2006 are not necessarily indicative of the results that may be expected for a full year. For further information, refer to the consolidated financial statements and footnotes for the year ended December 31, 2005, included in the Company’s Annual Report on Form 10-K.

NOTE B — USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. Significant estimates and assumptions for the Company relate to the allowance for doubtful accounts, the allowance for chargebacks, the allowance for rebates, the reserve for slow-moving and obsolete inventory, the allowance for product returns, the carrying value of intangible assets and the carrying value of deferred income tax assets.

NOTE C — STOCK BASED COMPENSATION

Effective January 1, 2006, the Company adopted Statement of Financial Accounting Standards No. 123 (revised 2004), “Share Based Payment” (SFAS 123(R)), applying the modified prospective method. Prior to the adoption of SFAS 123(R), the Company applied the provisions of APB Opinion No. 25, “Accounting for Stock Issued to Employees,” in accounting for its stock-based awards, and accordingly, recognized no compensation cost for its stock plans other than for its restricted stock awards.

Under the modified prospective method, SFAS 123(R) applies to new awards and to awards that were outstanding as of December 31, 2005 that are subsequently vested, modified, repurchased or cancelled. Compensation expense recognized during the first six months of 2006 includes the portion vesting during the period for (1) all share-based payments granted prior to, but not yet vested as of December 31, 2005, based on the grant date fair value estimated in accordance with the original provisions of Statement of Financial Accounting Standards No. 123, “Accounting for Stock-Based Compensation” (SFAS 123) and (2) all share-based payments granted subsequent to December 31, 2005, based on the grant-date fair value estimated using the Black-Scholes option-pricing model.

Stock option compensation expense of $498,000 and $701,000 was recognized during the three and six month periods ended June 30, 2006 of which $111,000 and $290,000 related to existing stock options granted prior to January 1, 2006 and $387,000 and $411,000 related to stock options granted during the current periods. As a result of the Company’s decision to adopt the modified prospective method, prior period results have not been restated. For awards issued prior to January 1, 2006, the Company used the multiple award method for allocating the compensation cost to each period. For awards issued on or after January 1, 2006, concurrent with the

adoption of SFAS 123(R), the Company has elected to use the single-award method for allocating the compensation cost to each period.

The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of SFAS 123 for the three and six months ended June 30, 2005 (in thousands, except for per share data).


	THREE MONTHS			SIX MONTHS
	ENDED			ENDED
	JUNE 30, 2005			JUNE 30, 2005

Net income (loss) as reported	$	(67	)	$	(2,354	)
Add: stock-based employee compensation expense included in reported net income		—			—
Deduct: total stock-based employee compensation expense determined under fair-value-based method for all awards		(373	)		(660	)

Pro forma net income (loss)		(440	)		(3,014	)
Deduct: preferred stock dividends and adjustments		(915	)		(1,976	)

Pro forma net loss available for common stockholders	$	(1,355	)	$	(4,990	)

Basic and diluted loss per share of common stock
Shares used in Computing Net Loss Per Share		25,961			25,601
As reported	$	(0.04	)	$	(0.17	)
Pro forma	$	(0.05	)	$	(0.19	)

The weighted-average assumptions used in estimating the fair value of the stock options granted during the period, along with the weighted-average grant date fair values, were as follows:


	THREE MONTHS			THREE MONTHS
	ENDED			ENDED
	JUNE 30, 2006			JUNE 30, 2005
	(SFAS 123(R))			(SFAS 123 Pro Forma)

Expected Volatility		45	%		64	%
Expected Life (in years)		3.6			5.0
Risk-free interest rate		5.0	%		3.9	%
Dividend yield		—			—
Fair value per stock option	$	1.91		$	1.51

A summary of stock based compensation activity within the Company’s stock-based compensation plans for the six months ended June 30, 2006 is as follows:


						Weighted Average
	Number of			Weighted		Remaining
	Shares			Average		Contractual Term		Aggregate
	(in thousands)			Exercise Price		(Years)		Intrinsic Value

Outstanding at January 1, 2006		3,706		$	2.54
Granted		890			4.85
Exercised		(656	)		2.32
Forfeited		(169	)		4.23

Outstanding at June 30, 2006		3,771		$	2.96		3.06	$	4,648

Exercisable at June 30, 2006		2,617		$	2.45		3.06	$	4,198

The aggregate intrinsic value for stock options outstanding and exercisable is defined as the difference between the market value of the Company’s stock as of the end of the period and the exercise price of the stock options. The total intrinsic value of stock options exercised during the three and six months ended June 30, 2006 was $204,000 and $1,507,000, respectively. As a result of the stock options exercised, the Company recorded cash received and additional paid-in-capital of $226,000 and $523,000 during the three and six months ended June 30, 2006.

The following is a summary of nonvested stock option activity:


	Number of Shares			Weighted Average
	(in thousands)			Grant Date Fair Value

Nonvested at December 31, 2005		842		$	1.94
Granted		890		$	1.93
Vested		(506	)	$	1.86
Canceled		(72	)	$	1.64

Nonvested at June 30, 2006		1,154		$	1.99

At June 30, 2006, there was $1,580,000 of total unrecognized compensation cost related to nonvested stock options. This cost will be recognized over 3 years.

The Company also grants restricted stock awards to certain employees. Restricted stock awards are valued at the closing market value of the Company’s common stock on the day of grant, and the total value of the award is recognized as expense ratably over the vesting period of the employees receiving the grants. The Company granted restricted stock awards valued at $1,767,000 during the second quarter of 2006. As of June 30, 2006, the total amount of unrecognized compensation expense related to nonvested restricted stock awards was $1,620,000. The Company recognized compensation expense of $147,000 and $277,000 during the three and six-month periods ended June 30, 2006, respectively, related to outstanding restricted stock awards.

NOTE D — REVENUE RECOGNITION

The Company recognizes product sales for its ophthalmic and hospital drugs & injectables business segments upon the shipment of goods or upon the delivery of goods, depending on the sales terms. Revenue is recognized when all obligations of the Company have been fulfilled and collection of the related receivable is probable.

The contract services segment, which produces products for third party customers based upon their specifications and at pre-determined prices, also recognizes sales upon the shipment of goods or upon delivery of the product or service as appropriate. Revenue is recognized when all obligations of the Company have been fulfilled and collection of the related receivable is probable.

Provision for estimated doubtful accounts, chargebacks, rebates, discounts and product returns is made at the time of sale and is analyzed and adjusted, if necessary, at each balance sheet date.

NOTE E — ACCOUNTS RECEIVABLE ALLOWANCES & CUSTOMER ACCRUED LIABILITIES

The nature of the Company’s business inherently involves, in the ordinary course, significant amounts and substantial volumes of transactions and estimates relating to allowances for doubtful accounts, product returns, chargebacks, rebates and discounts given to customers. This is a natural circumstance of the pharmaceutical industry and not specific to the Company and inherently lengthens the collection process. Depending on the product, the end-user customer, the specific terms of national supply contracts and the particular arrangements with the Company’s wholesaler customers, certain rebates, chargebacks and other credits are deducted from the Company’s accounts receivable. The process of claiming these deductions depends on wholesalers reporting to the Company the amount of deductions that were earned under the respective terms with end-user customers (which in turn depends on which end-user customer, with different pricing arrangements might be entitled to a particular deduction). This process can lead to “partial payments” against outstanding invoices as the wholesalers take the claimed deductions at the time of payment.

The provisions for the following customer reserves are reflected in the accompanying financial statements as reductions of revenues in the income statement with the exception of the allowance for doubtful accounts which is reflected as part of selling, general and administrative expense. The ending reserve amounts are included in the net trade accounts receivable and customer accrued liabilities in the balance sheet.

Net trade accounts receivable consists of the following (in thousands):


	JUNE 30,			DECEMBER 31,
	2006			2005
Gross Accounts Receivable	$	13,822		$	12,642
Less:
Allowance for Doubtful Accounts		(3	)		(13	)
Returns Reserve		(1,504	)		(1,529	)
Discount and Allowances Reserve		(347	)		(244	)
Chargeback and Rebates Reserves		(6,981	)		(7,634	)

Net Trade Accounts Receivable	$	4,987		$	3,222

Customer Accrued Liabilities consists of the following (in thousands):


	JUNE 30,			DECEMBER 31,
	2006			2005
Customer advance payments and net refunds liability	$	(332	)	$	(135	)

Total Customer Accrued Liability	$	(332	)	$	(135	)

For the three-month periods ended June 30, 2006 and 2005, the Company recorded chargeback and rebate expense of $8,100,000 and $7,027,000, respectively. For the six month periods ended June 30, 2006 and 2005, the Company recorded chargeback and rebate expense of $11,743,000 and $12,026,000, respectively. This decrease was primarily due to reduced sales to wholesalers.

For the three-month periods ended June 30, 2006 and 2005, the Company recorded a provision for product returns of $760,000 and $626,000, respectively. For the six-month periods ended June 30, 2006 and 2005, the Company recorded a provision for product returns of $1,607,000 and $1,058,000, respectively. The increase in the provision was to recognize unfavorable customer returns experience in the period.

For the three-month periods ended June 30, 2006 and 2005, the Company recorded a net benefit for doubtful accounts of $21,000 and $48,000, respectively as recoveries exceeded uncollectible amounts written off. For the six-month periods ended June 30, 2006 and 2005, the Company recorded a net benefit for doubtful accounts of $88,000 and $117,000, respectively.

For the three-month periods ended June 30, 2006 and 2005, the Company recorded a provision for cash discounts of $362,000 and $297,000, respectively. For the six-month periods ended June 30, 2006 and 2005, the Company recorded a provision for cash discounts of $952,000 and $476,000, respectively. This increase primarily related to a cash discount for a large sale of the Company’s antidote products (see Management’s Discussion and Analysis of Financial Condition and Results of Operations below).

NOTE F — INVENTORIES

The components of inventories are as follows (in thousands):


	JUNE 30,		DECEMBER 31,
	2006		2005
Finished goods	$	3,521	$	4,914
Work in process		2,551		1,702
Raw materials and supplies		4,898		3,663

	$	10,970	$	10,279

Inventory at June 30, 2006 and December 31, 2005 is reported net of reserves for slow-moving, unsalable and obsolete items of $839,000 and $916,000, respectively, primarily related to finished goods. For the three-month periods ended June 30, 2006 and 2005, the Company recorded a provision of $(33,000) and $179,000, respectively. The second quarter 2006 provision reduction was a result

of sales for previously reserved products. For the six-month periods ended June 30, 2006 and 2005, the Company recorded a provision of $200,000 and $204,000, respectively.

NOTE G — PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consists of the following (in thousands):


	JUNE 30,			DECEMBER 31,
	2006			2005
Land	$	396		$	396
Buildings and leasehold improvements		9,433			9,393
Furniture and equipment		28,364			27,866
Automobiles		55			55

Sub-total		38,248			37,710
Accumulated depreciation		(27,823	)		(26,879	)

		10,425			10,831
Construction in progress		21,090			20,240

Property, Plant, & Equipment, net	$	31,515		$	31,071

Construction in progress primarily represents capital expenditures related to the Company’s Lyophilization project. The Company anticipates completing its lyophilization facility validation and having a pre-approval inspection (“PAI”) by the U.S. Food and Drug Administration (“FDA”) in the second half of 2006. Future costs are estimated to be approximately $600,000. The Company can make no assurances that it will be able to complete this project within its estimated timeframe, or at all, or that material impairment charges will not be required if such completion does not occur as anticipated. The commissioning of the lyophilization facility is contingent upon a successful PAI to be conducted by the FDA.

NOTE H — FINANCING ARRANGEMENTS

The Company’s long-term debt consists of (in thousands):


	JUNE 30,			DECEMBER 31,
	2006			2005
2003 Subordinated Notes	$	—		$	2,767
Convertible subordinated debentures		—			5,000
Mortgages payable		788			938

		788			8,705
Less unamortized discount on debt		—			(1,059	)
Less current installments of debt		(380	)		(7,044	)

Long-term debt	$	408		$	602

On September 30, 2005, the Company renewed its credit agreement (the “Credit Facility”) with LaSalle Bank National Association (“LaSalle Bank”). The renewal extended the existing Credit Facility until September 30, 2008 and increased the Revolving Commitment amount (the “Revolver”) from $5,000,000 to $10,000,000, as well as made modifications of prior existing covenants and the addition of a tangible net worth financial covenant. The borrowing rate was reduced to the LaSalle prime rate (8.25% at June 30, 2006) plus 0.5% from the previous rate of LaSalle prime plus 1.5%. On June 30, 2006, the Company had $8,460,000 of undrawn availability under the Credit Facility which is based on its level of accounts receivable and inventory and certain equipment as of June 30, 2006. There was no borrowing against the Revolver at June 30, 2006.

On October 7, 2003, the Company issued subordinated promissory notes in the aggregate principal amount of $2,767,000 (the “2003 Subordinated Notes”) along with warrants to purchase 276,714 shares of common stock at an exercise price of $1.10 per share to the John N. Kapoor Trust dated 9/20/89 (the “Kapoor Trust”), Arjun C. Waney and Argent Fund Management, Ltd. The 2003 Subordinated Notes were to mature on April 7, 2006 and bore interest at prime plus 1.75%, but interest payments were prohibited under the terms of the Company’s subordination agreement. With the consent of LaSalle Bank, the Company retired the 2003 Subordinated Notes with cash payments totaling $3,288,000 on March 20, 2006. The unamortized debt discount related to the 2003 Subordinated Notes was $113,000 at December 31, 2005. Related debt discount amortization was zero and $121,000 for the three months ended June 30, 2006 and 2005, respectively. Related debt discount amortization was $113,000 and $209,000 for the six months ended June 30, 2006 and 2005, respectively.

In 2001, the Company entered into a $5,000,000 convertible subordinated debt agreement, which included a $3,000,000 Tranche A note (“Tranche A Note”) and a $2,000,000 Tranche B note (“Tranche B Note”), with the Kapoor Trust (collectively, the “Convertible Note Agreement”). Under the terms of the Convertible Note Agreement, both the Tranche A Note and the Tranche B Note, which were due December 20, 2006, bore interest at prime plus 3% and were issued with detachable warrants (the “Tranche A Warrants” and the “Tranche B Warrants”) to purchase shares of common stock.

Interest payments for the Tranche A Note and the Tranche B Note were prohibited under the terms of a subordination arrangement. The convertible feature of the Convertible Note Agreement, as amended, allowed for conversion of the subordinated debt plus interest into the Company’s common stock, at a price of $2.28 per share of common stock for the Tranche A Note and $1.80 per share of common stock for the Tranche B Note. The convertible feature on the accrued interest could generate separately recordable beneficial conversion amounts when the price of the Company’s common stock was higher than the conversion rate when the interest was accrued. The beneficial conversion amount related to interest was zero and $41,000 for the three month periods ended June 30, 2006 and 2005, respectively, and was recorded as an increase to paid-in-capital and as additional debt discount amortizable over the remaining term of the convertible subordinated debt. The beneficial conversion amount related to interest was zero and $139,000 for the six month periods ended June 30, 2006 and 2005, respectively.

The Company negotiated an early settlement of the Tranche A Note and the Tranche B Note in March 2006. The associated principal and accumulated interest of approximately $7,298,000 was retired by conversion into 3,540,281 shares of the Company’s common stock on March 31, 2006. A debt retirement fee of approximately $391,000 was paid as an inducement to retire these notes prior to the original maturity date of December 20, 2006.

Unamortized debt discount related to the Tranche A Note and the Tranche B Note was $428,000 at December 31, 2005. Related debt discount amortization was zero and $178,000 for the three months ended June 30, 2006 and 2005, respectively. Related debt discount amortization was $428,000 and $343,000 for the six months ended June 30, 2006 and 2005, respectively.

In June 1998, the Company entered into a $3,000,000 mortgage agreement with Standard Mortgage Investors, LLC of which there were outstanding borrowings of $788,000 and $938,000 at June 30, 2006 and December 31, 2005, respectively. The principal balance is payable over 10 years, with the final payment due in June 2008. The mortgage note bears a fixed interest rate of 7.375% and is secured by the real property located in Decatur, Illinois.

NOTE I — COMMON STOCK ISSUANCE

On March 8, 2006 the Company issued 4,311,669 shares of its common stock in a private placement with various investors at a price of $4.50 per share which included warrants to purchase 1,509,088 additional shares of common stock. The warrants are exercisable for a five year period at an exercise price of $5.40 per share and may be exercised by cash payment of the exercise price or by means of a cashless exercise. The aggregate offering price of the private placement was approximately $19,402,000 and the net proceeds to the Company, after payment of approximately $1,324,000 of commissions and expenses, was approximately $18,078,000.

The net proceeds of $18,078,000 were allocated based on the relative fair market values of the common stock and warrants with $16,257,000 allocated to the common stock and $1,821,000 allocated to the warrants.

NOTE J — EARNINGS PER COMMON SHARE

Basic net income (loss) per common share is based upon weighted average common shares outstanding. Diluted net income (loss) per common share is based upon the weighted average number of common shares outstanding, including the dilutive effect of convertible preferred stock, stock options, warrants and convertible debt using the treasury stock and if converted methods. However, for the three months ended June 30, 2006 and the three and six-month periods ended June 30, 2005, the assumed exercise or conversion of any of these securities would have been anti-dilutive; and, accordingly, the diluted loss per share equals the basic loss per share for those periods. A reconciliation of the earnings per share data from a basic to a fully diluted basis is detailed below:


	THREE MONTHS ENDED						SIX MONTHS ENDED
	JUNE 30,			JUNE 30,			JUNE 30,		JUNE 30,
Fully Diluted Earnings Per Share Data	2006			2005			2006		2005
Net income (loss) available to common stockholders — basic	$	(2,197	)	$	(982	)	$	603	$	(4,330	)
Preferred stock dividends adjustment		—			—			—		—

Adjusted earnings – fully diluted basis	$	(2,197	)	$	(982	)	$	603	$	(4,330	)


Basic Shares		74,853			25,961			68,321		25,601
Warrants		—			—			6,610		—
Options		—			—			1,550		—

Fully Diluted Shares		74,853			25,961			76,481		25,601

NOTE K — INDUSTRY SEGMENT INFORMATION

The Company classifies its operations into three business segments, ophthalmic, hospital drugs & injectables and contract services. The ophthalmic segment manufactures, markets and distributes diagnostic and therapeutic pharmaceuticals. The hospital drugs & injectables segment manufactures, markets and distributes drugs and injectable pharmaceuticals, primarily in niche markets. This segment was previously classified as the injectable segment; however, the Company recently changed the classification to reflect that an increasing amount of pharmaceuticals delivered by the Company to hospitals are drugs other than injectable pharmaceuticals. The new classification reflects that the segment includes both hospital drugs and injectable pharmaceuticals. The contract services segment manufactures products for third party pharmaceutical and biotechnology customers based on their specifications. Selected financial information by industry segment is presented below (in thousands).


	THREE MONTHS ENDED JUNE 30,						SIX MONTHS ENDED JUNE 30,
	2006			2005			2006			2005
REVENUES
Ophthalmic	$	5,703		$	6,227		$	9,510		$	11,323
Hospital Drugs & Injectables		5,104			4,362			29,001			7,263
Contract Services		1,668			1,989			3,694			4,173

Total revenues	$	12,475		$	12,578		$	42,205		$	22,759

GROSS PROFIT
Ophthalmic	$	2,287		$	2,390		$	3,285		$	4,192
Hospital Drugs & Injectables		2,190			2,151			12,367			3,375
Contract Services		478			311			1,036			628

Total gross profit		4,955			4,852			16,688			8,195
Operating expenses		7,140			5,547			14,020			10,636

Operating income (loss)		(2,185	)		(695	)		2,668			(2,441	)
Interest & Other income (expense)		222			(584	)		(1,114	)		(1,110	)
Debt Retirement gain/(expense)		—			1,212			(391	)		1,212

Income/(Loss) before income taxes	$	(1,963	)	$	(67	)	$	1,163		$	(2,339	)

The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis. Intersegment activity at the gross profit level is minimal. The Company does not identify assets by segment for internal purposes, as certain manufacturing and warehouse facilities support more than one segment.

NOTE L — COMMITMENTS AND CONTINGENCIES

The FDA issued the Company a warning letter (“Warning Letter”) in October 2000 following a routine inspection of its Decatur manufacturing facility. An FDA warning letter is intended to provide notice to a company of violations of the laws administered by the FDA and to elicit voluntary corrective action. The Warning Letter cited violations of regulatory requirements identified during the 2000 inspection and requested that the Company take corrective actions. Under the terms of the Warning Letter, the Company was unable to obtain any approvals to market new products and government agencies were notified of its non-compliant status. Additional FDA inspections in 2002, 2003 and 2004 identified additional and recurring violations resulting in continuance of the Warning Letter. During this time, the FDA initiated no enforcement action.

Since 2000, and in response to the violations cited by the FDA, the Company has implemented a comprehensive systematic corrective action plan at its Decatur manufacturing facility. The Company maintained regular communications with the FDA and provided periodic progress reports.

On December 13, 2005, the FDA notified the Company that it had satisfactorily implemented corrective actions and the FDA had determined that the Decatur manufacturing facility was in substantial compliance with current Good Manufacturing Practices regulations. Consequently, the restrictions of the Warning Letter were removed and the Company became eligible for new product approvals for products manufactured at its Decatur manufacturing facility.

While under the Warning Letter restrictions from 2000 to 2005, the Company’s inability to fully utilize the capabilities of the Decatur manufacturing facility had a material adverse effect on its business, financial condition and results of operations.

The Company anticipates completing its lyophilization facility validation and having a PAI by the FDA in the second half of 2006. However, the commissioning of the lyophilization facility is contingent upon a successful PAI to be conducted by the FDA.

The Company is a party in legal proceedings and potential claims arising in the ordinary course of its business. The amount, if any, of ultimate liability with respect to such matters cannot be determined. Despite the inherent uncertainties of litigation, management of the Company at this time does not believe that such proceedings will have a material adverse impact on the financial condition, results of operations, or cash flows of the Company.

NOTE M — CUSTOMER AND SUPPLIER CONCENTRATION

The Company’s major customer for the six month period ended June 30, 2006 was the United States Department of Health and Human Services (“HHS”) which purchased $21,962,000 of the Company’s injectable antidote products during the first quarter of 2006. The Company did not sell to HHS in 2005. AmerisourceBergen Health Corporation (“Amerisource”), Cardinal Health, Inc. (“Cardinal”) and McKesson Drug Company (“McKesson”) are all distributors of the Company’s products, as well as suppliers of a broad range of health care products. These three customers accounted for 74% and 63% of the Company’s gross revenues and 58% and 51% of net revenues for the three months ended June 30, 2006 and 2005, respectively. They accounted for approximately 82% and 71% of the gross accounts receivable balances as of June 30, 2006 and 2005, respectively. These three customers accounted for 40% and 59% of the Company’s gross revenues and 24% and 44% of net revenues for the six months ended June 30, 2006 and 2005, respectively. No other customers accounted for more than 10% of gross sales, net revenues or gross trade receivables for the indicated dates and periods.

If sales to any of Amerisource, Cardinal or McKesson were to diminish or cease, the Company believes that the end users of its products would find little difficulty obtaining the Company’s products either directly from the Company or from another distributor.

No supplier of products accounted for more than 10% of the Company’s purchases in the three months ended June 30, 2006. For the three months ended June 30, 2005, Cardinal Health PTS, LLC accounted for 22% of the Company’s purchases. For the six months ended June 30, 2006, Hameln Pharmaceuticals GmbH accounted for 20% of the Company’s purchases. For the six months ended June 30, 2005, Cardinal Health PTS, LLC accounted for 27% of the Company’s purchases.

The Company requires a supply of quality raw materials and components to manufacture and package pharmaceutical products for its own use and for third parties with which it has contracted. The principal components of the Company’s products are active and inactive pharmaceutical ingredients and certain packaging materials. Certain of these ingredients and components are available from only a single source and, in the case of certain of the Company’s Abbreviated New Drug Applications (“ANDAs”) and New Drug Applications (“NDAs”), only one supplier of raw materials has been identified. Because FDA approval of drugs requires manufacturers to specify their proposed suppliers of active ingredients and certain packaging materials in their applications, FDA approval of any new supplier would be required if active ingredients or such packaging materials were no longer available from the specified supplier. The qualification of a new supplier could delay the Company’s development and marketing efforts. If for any reason the Company is unable to obtain sufficient quantities of any of the raw materials or components required to produce and package its products, it may not be able to manufacture its products as planned, which could have a material adverse effect on the Company’s business, financial condition and results of operations.

Item 2.

AKORN, INC.

MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS AND FACTORS AFFECTING FUTURE RESULTS

Certain statements in this Form 10-Q constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. When used in this document, the words “anticipate,” “believe,” “estimate” and “expect” and similar expressions are generally intended to identify forward-looking statements. Any forward-looking statements, including statements regarding the intent, belief or expectations of Akorn or its management are not guarantees of future performance. These statements involve risks and uncertainties and actual results may differ materially from those in the forward-looking statements as a result of various factors, including but not limited to:

	•		Our ability to comply with all of the requirements of the FDA, including current Good Manufacturing Practices regulations;

	•		Our ability to obtain regulatory approvals of, commence operations at and obtain business for our new lyophilization facility;

	•		Our ability to avoid defaults under debt covenants;

	•		Our ability to generate cash from operations sufficient to meet our working capital requirements;

	•		The effects of federal, state and other governmental regulation on our business;

	•		Our success in developing, manufacturing, acquiring and marketing new products;

	•		The success of our strategic partnerships for the development and marketing of new products;

	•		Our ability to bring new products to market and the effects of sales of such products on our financial results;

	•		The effects of competition from generic pharmaceuticals and from other pharmaceutical companies;

	•		Availability of raw materials needed to produce our products; and

	•		Other factors referred to in this Form 10-Q, our Form 10-K and our other Securities and Exchange Commission (“SEC”) filings.

RESULTS OF OPERATIONS

THREE MONTHS ENDED JUNE 30, 2006 COMPARED TO 2005

The following table sets forth, for the periods indicated, revenues by segment, excluding intersegment sales (in thousands):


	THREE MONTHS ENDED JUNE 30,
	2006		2005
Ophthalmic segment	$	5,703	$	6,227
Hospital Drugs & Injectables segment		5,104		4,362
Contract Services segment		1,668		1,989

Total revenues	$	12,475	$	12,578

Consolidated revenues decreased $103,000 or 0.8% in the quarter ended June 30, 2006 compared to the same period in 2005. This was a result of increases in injectable products with the launch of Inapsine^® and higher volumes on anesthetic products offset by the planned reduction in ophthalmic diagnostic product sales to wholesalers to reduce wholesaler inventory stocking levels. Our contract services segment revenues decreased by $321,000 or 16.1% mainly due to the timing for a customer order that was delayed until early July 2006.

Consolidated gross profit was $4,955,000 or 39.7% for the second quarter of 2006 as compared to a gross profit of $4,852,000 or 38.6% in the same period a year ago mainly due to the sales volume variation matters for each segment discussed above. We continue to seek margin enhancement opportunities through our product offerings as well as through cost reductions at our operating facilities.

Selling, general and administrative (“SG&A”) expenses increased by $970,000 or 26.2%, during the quarter ended June 30, 2006 as compared to the same period in 2005. The key components of this increase in 2006 were: management bonus expense of $300,000 and SFAS 123(R) stock option compensation expense of $498,000 for 2006.

Research and development (“R&D”) expense increased $698,000 or 49.1% in the quarter, to $2,121,000 from $1,423,000 for the same period in 2005 mainly due to continued testing and development of our lyophilization processes ($674,000), increased spending on improvements in regulatory compliance measures ($319,000), and spending on new product development ($268,000) in 2006. This increase in R&D expense was partially offset by a reduction in product development expenses for the Joint Venture Company of approximately $563,000.

Interest income for the second quarter of 2006 was $234,000 versus interest expense of $584,000 for the same period in 2005 as we retired our major debt instruments in early 2006 and invested our cash proceeds from our operations and the March 2006 common stock and warrant offering.

For the three-month period ended June 30, 2006 the income tax provision was zero due to the loss and also zero in the same 2005 period as we utilized prior period losses to offset the tax on the income in the second quarter of 2005.

We reported a net loss of $1,963,000 for the three months ended June 30, 2006, versus a net loss of $67,000 for the same period in 2005 mainly due to the increased administrative and research expenses discussed above and the impact of the $1,212,000 gain realized in May 2005 from retiring the NeoPharm debt. See Item 8. Financial Statements and Supplementary Data, Note G – Financing Arrangements in our Form 10-K filed March 30, 2006, for further information regarding the retirement of the NeoPharm debt.

SIX MONTHS ENDED JUNE 30, 2006 COMPARED TO 2005

The following table sets forth, for the periods indicated, revenues by segment, excluding intersegment sales (in thousands):


	SIX MONTHS ENDED JUNE 30,
	2006		2005
Ophthalmic segment	$	9,510	$	11,323
Hospital Drugs & Injectables segment		29,001		7,263
Contract Services segment		3,694		4,173

Total revenues	$	42,205	$	22,759

Consolidated revenues increased $19,446,000 or 85.4% for the six months ended June 30, 2006 compared to the same period in 2005. This was mainly due to the $21,962,000 sale of injectable antidote products to HHS partially offset by a planned reduction in ophthalmic sales to wholesalers to reduce wholesaler inventory stocking levels. Our contract services segment revenues decreased by $479,000 or 11.5% mainly due to the timing for a customer order that was delayed until early July 2006 and reduced first quarter demand for contract manufacturing and research services.

YTD consolidated gross profit was $16,688,000 or 39.5% for 2006 as compared to a gross profit of $8,195,000 or 36.0% for the same period a year ago mainly due to the sales volume variation matters for each segment discussed above. We continue to seek margin enhancement opportunities through our product offerings as well as through cost reductions at our operating facilities.

SG&A expenses increased by $2,086,000 or 29.5%, for the year to date period ended June 30, 2006 as compared to the same period in 2005. The key components of this increase in 2006 were management bonus expense of $851,000, increased restricted stock compensation expense of $127,000 and $701,000 in SFAS 123(R) stock option compensation expense for 2006.

R&D expense increased $1,401,000 or 50.7% for the six months ended June 30, 2006, to $4,166,000 from $2,765,000 for the same period in 2005 mainly due to continued testing and development of our lyophilization processes ($1,355,000), increased spending on improvements in regulatory compliance measures ($724,000), and spending on new product development ($573,000) in 2006. This increase in R&D expense was partially offset by a reduction in product development expenses for the Joint Venture Company of approximately $1,251,000.

Interest expense for the six month period ended June 30, 2006 was $1,085,000 versus $1,110,000 for the same period in 2005. The change compared to the same period in the prior year was mainly due to the $1,059,000 of amortization of debt discount in accordance with retiring the convertible debt and subordinated notes in the first quarter of 2006 which was partially offset by lower interest cost in accordance with retiring that debt and interest earned from investing our cash proceeds from operations and the March 2006 common stock and warrant offering.

For the six-month period ended June 30, 2006 the income tax provision was zero as we are utilizing prior years tax losses to offset the tax liability on income in 2006.

We reported net income of $1,163,000 for the six months ended June 30, 2006, versus a net loss of $2,354,000 for the same period in 2005 mainly due to the increase in revenues discussed above and the $1,212,000 impact of the 2005 NeoPharm debt retirement gain in 2005. See Item 8. Financial Statements and Supplementary Data, Note G – Financing Arrangements in our Form 10-K filed March 30, 2006, for further information regarding the retirement of the NeoPharm debt.

FINANCIAL CONDITION AND LIQUIDITY

Overview

During the six-month period ended June 30, 2006, we generated $2,029,000 in cash provided from operations, primarily due to $1,163,000 in net income generated by the increase in sales, a $2,816,000 change in working capital items mainly due to lower receivables levels with wholesalers and non-cash expenses of $3,682,000 for the period. Investing activities generated a $1,388,000 reduction in cash flow mainly due to capital expenditures for production equipment. Financing activities provided $16,349,000 in cash, due to the $18,078,000 net proceeds from the March 2006 common stock and warrants offering (see Item 1. Financial Statements, Note I – Common Stock Issuance), offset by $2,917,000 repayment of long-term debt. In addition, on March 31, 2006 $7,298,000 in principal and accrued interest on the convertible notes was retired by conversion into 3,540,281 shares of our common stock (see Item 1. Financial Statements, Note H – Financing Arrangements).

During the six-month period ended June 30, 2005, we used $2,118,000 in cash from operations, primarily due to the net loss, offset by non-cash adjustments for amortization and depreciation, a $2,382,000 decrease in accounts payable and a $1,500,000 advance to our joint venture partner (Strides) to develop ANDAs and by an $849,000 decrease in accounts receivable. Investing activities during the six-month period ended June 30, 2005 include a $75,000 licensing fee, as well as $357,000 of capital expenditures primarily related to the lyophilized (freeze-dried) pharmaceuticals manufacturing line expansion. Financing activities used $1,523,000 in cash, due to the $2,500,000 repayment of the NeoPharm Note, offset by proceeds from stock option and warrant exercises as well as borrowings on our line of credit of $663,000.

As of June 30, 2006, we had $17,781,000 in cash and $8,460,000 of undrawn availability under our Credit Facility with LaSalle Bank (the “Credit Facility”) which is based on its level of accounts receivable and inventory and certain equipment as of June 30, 2006. There was no borrowing against the Revolver at June 30, 2006.

Facility Expansion

We are in the process of completing an expansion of our Decatur, Illinois manufacturing facility to add capacity to provide lyophilization manufacturing services, a manufacturing capability we currently do not have. As of June 30, 2006, we had spent approximately $20,318,000 on the lyophilization expansion and anticipate the need to spend approximately $600,000 of additional funds to complete the expansion. The majority of the additional spending will be focused on validation testing of the lyophilization facility as the major capital equipment items are currently in place.

Commissioning of the lyophilization facility in 2006 will be contingent upon a successful pre-approval inspection to be conducted by the FDA. Manufacturing capabilities for lyophilized products are subsequently projected to be in service by the fourth quarter of 2006.

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. A summary of our significant accounting policies is included in Item 1. Financial Statements, Note B – Summary of Significant Accounting Policies , which are included in our Annual Report on Form 10-K for the year ended December 31, 2005. Certain of our accounting policies are considered critical, as these policies require significant, difficult or complex judgments by management, often employing the use of estimates about the effects of matters that are inherently uncertain. Such policies are summarized in Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the year ended December 31, 2005. There have been no significant changes in the application of the critical accounting policies since December 31, 2005.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

At December 31, 2005, we were subject to market risk associated with changes in interest rates involving two debt instruments. Debt under the 2003 Subordinated Notes bore interest at prime plus 1.75%. Each of the Tranche A and Tranche B Notes bore interest at prime plus 3.0%. We estimated that a change of 1% in our variable rate debt from interest rates in effect at December 31, 2005 would have resulted in a $105,000 pre-tax change in annual interest expense.

We are no longer affected by changes in market interest rates as our variable interest rate debt has been paid off (See Item 1. Financial Statements, Note H – Financing Arrangements). At June 30, 2006, our only outstanding debt is the mortgage on our Decatur property which is set at a fixed rate of 7.375%.

ITEM 4. CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934, as amended (“Exchange Act”) reports is recorded, processed, summarized and reported within the periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in timely communicating to them the material information relating to us required to be included in our periodic SEC filings.

There were no changes to our internal controls over financial reporting that occurred during our most recently completed fiscal quarter that materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are a party in legal proceedings and potential claims arising in the ordinary course of our business. The amount, if any, of ultimate liability with respect to such matters cannot be determined. Despite the inherent uncertainties of litigation, we at this time do not believe that such proceedings will have a material adverse impact on the financial condition, results of operations, or cash flows of us.

ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors disclosed in Part 1, Item 1A, of our Form 10-K filed March 30, 2006.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On August 23, 2005, we filed a Registration Statement on Form S-3 (File No. 333-127794) (the “S-3”) with the SEC, which was declared effective on September 7, 2005. Pursuant to Rule 429 under the Securities Act of 1933, the prospectus included in the S-3 is a combined prospectus and relates to the previously filed Registration Statement on Form S-1 (File No. 333-119168) (the “S-1”), as to which the S-3 constitutes Post-Effective Amendment No. 3. Such Post-Effective Amendment became effective concurrently with the effectiveness of the S-3. The S-3 relates to the resale of 64,964,680 shares, no par value per share, of our common stock by the selling stockholders identified in the S-3, which have been issued or reserved for issuance upon the conversion or exercise of presently outstanding shares of our Series A 6.0% Participating Convertible Preferred Stock (“Series A Preferred Stock”), shares of Series B 6.0% Participating Convertible Preferred Stock (“Series B Preferred Stock”), warrants and convertible notes, including shares estimated to be issuable in satisfaction of accrued and unpaid dividends and interest on shares of preferred stock and convertible notes, respectively. Of the 64,964,680 shares of our common stock registered under the S-3, 60,953,394 of such shares were registered under the S-1. The shares of common stock registered by the S-3 and the S-1 represent the number of shares that have been issued or are issuable upon the conversion or exercise of the Series A Preferred Stock, Series B Preferred Stock, warrants and convertible notes described in the Registration Statement, including shares estimated to be issuable in satisfaction of dividends accrued and unpaid through December 31, 2007 and interest accrued and unpaid through December 20, 2006 on such securities.

With respect to the S-1, we estimated the aggregate offering price of the amount registered to be $182,246,053, which was derived from the average of the bid and asked prices of our common stock on September 17, 2004, as reported on the OTC Bulletin Board(R). With respect to the S-3, we estimated the aggregate offering price of the amount registered to be $10,870,585, which was derived from the average of the high and low prices of our common stock as reported on the American Stock Exchange on August 18, 2005. Such amounts were estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) under the Securities Act of 1933. As of July 31, 2006, we are aware of the sale of 4,304,730 shares of common stock by selling stockholders under the S-3 or the S-1. We do not know at what price such shares were sold, or how many shares of common stock will be sold in the future or at what price. We have not and will not receive any of the proceeds from the sale of the shares by the selling stockholders. The selling stockholders will receive all of the proceeds from the sale of the shares and will pay all underwriting discounts and selling commissions, if any, applicable to the sale of the shares. We will, in the ordinary course of business, receive proceeds from the issuance of shares upon exercise of the warrants described in the S-3 or the S-1, which we will use for working capital and other general corporate purposes.

For the quarter ended June 30, 2006, we issued the following equity securities: (i) On April 18, 2006, a holder of our Series B Preferred Stock converted 2,963 shares of such stock plus accrued dividends of $30,717 into 121,117 shares of our common stock at a conversion price of $2.70 per share, (ii) On May 3, 2006, a holder of warrants to purchase shares of our common stock exercised such warrants to purchase 50,000 shares of our common stock at an exercise price of $0.75 per share in exchange for cash of $37,500, (iii) On May 11, 2006, a holder of warrants to purchase shares of our common stock exercised such warrants to purchase 150,000 shares of our common stock at an exercise price of $0.75 per share in exchange for cash of $112,500, (iv) On May 23, 2006, a holder of warrants to purchase shares of our common stock exercised such warrants to purchase 333,333 shares of our common stock at an exercise price of $1.00 per share in exchange for cash of $333,333, (v) On June 8, 2006, a holder of warrants to purchase shares of our common stock exercised such warrants to purchase 3,333 shares of our common stock at an exercise price of $1.00 per share by providing us with notice of election to exercise on a cashless exercise basis. By exercising on a cashless basis, the number of shares of common stock that would otherwise be issuable upon the exercise of such warrants was reduced by 768 shares, an aggregate value of $3,333 as of the exercise date. Accordingly, such holder was issued 2,565 shares of our common stock upon exercise of such, and (vi) On June 23, 2006, a holder of warrants to purchase shares of our common stock exercised such warrants to purchase 88,495 shares of our common stock at an exercise price of $3.50 per share in exchange for cash of $309,733. The issuance of the common stock upon conversion of the Series B Stock was exempt from the registration requirements under the Securities Act of 1933, as amended, pursuant to Section 4(2) and/or Section 3(a)(9) thereof, because the conversion did not involve public offering and the shares of Series B Stock were exchanged for shares of the common stock exclusively with a holder of our Series B Stock and no commission or other remuneration was paid or given directly or indirectly for soliciting such exchange. The issuance of the common stock upon exercise of the warrants described herein was exempt from the registration requirements under the Securities Act of 1933, as amended, pursuant to Section 4(2) thereof, because none of the transactions involved a public offering.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 6. EXHIBITS

Those exhibits marked with an asterisk (*) refer to exhibits filed herewith. The other exhibits are incorporated herein by reference, as indicated in the following list.


Exhibit No.		Description
(3.1)		Restated Articles of Incorporation of Akorn, Inc. dated September 16, 2004, incorporated by reference to Exhibit 3.1 to Akorn, Inc.’s Registration Statement on Form S-1 filed on September 21, 2004.

(3.2)		Amendment and Restated By-laws of Akorn, Inc. incorporated by reference to Exhibit 3.2 to Akorn, Inc.’s Registration Statement on Form S-1 filed on June 14, 2005.

(3.3)		Amendment to By-laws of Akorn, Inc. incorporated by reference to Exhibit 3.1 to the Akorn, Inc.’s report on Form 8-K filed on March 31, 2006.

(4.1)		First Amendment dated October 7, 2003 to Registration Rights Agreement dated July 12, 2001 between Akorn, Inc. and The John N. Kapoor Trust dated 9/20/89, incorporated by reference to Exhibit 4.1 to Akorn, Inc.’s report on Form 8-K filed on October 24, 2003.

(4.2)		Form of Warrant Certificate, incorporated by reference to Exhibit 4.2 to Akorn, Inc.’s report on Form 8-K filed on October 24, 2003.

(4.3)		Form of Warrant Agreement dated October 7, 2003 between Akorn, Inc. and certain investors, incorporated by reference to Exhibit 4.3 to Akorn, Inc.’s report on Form 8-K filed on October 24, 2003.

(4.4)		Warrant Agreement dated October 7, 2003 between Akorn, Inc. and The John N. Kapoor Trust dated 9/20/89 issued with respect to New Credit Facility guaranty, incorporated by reference to Exhibit 4.4 to Akorn, Inc.’s report on Form 8-K filed on October 24, 2003.

(4.5)		Warrant Agreement dated October 7, 2003 between Akorn, Inc. and Arjun C. Waney issued with respect to New Credit Facility guaranty, incorporated by reference to Exhibit 4.5 to Akorn, Inc.’s report on Form 8-K filed on October 24, 2003.

(4.6)		Warrant Agreement dated October 7, 2003 between Akorn, Inc. and The John N. Kapoor Trust dated 9/20/89 issued with respect to the Notes, incorporated by reference to Exhibit 4.6 to Akorn, Inc.’s report on Form 8-K filed on October 24, 2003.

(4.7)		Warrant Agreement dated October 7, 2003 between Akorn, Inc. and Arjun C. Waney issued with respect to the Notes, incorporated by reference to Exhibit 4.7 to the Akorn, Inc.’s report on Form 8-K filed on October 24, 2003.

(4.8)		Warrant Agreement dated October 7, 2003 between Akorn, Inc. and Argent Fund Management Ltd. issued with respect to the Notes, incorporated by reference to Exhibit 4.8 to Akorn, Inc.’s report on Form 8-K filed on October 24, 2003.

(4.9)		Registration Rights Agreement dated October 7, 2003 among Akorn, Inc. and certain investors, incorporated by reference to Exhibit 4.9 to Akorn, Inc.’s report on Form 8-K filed on October 24, 2003.

(4.10)		Form of Subscription Agreement between Akorn, Inc. and certain investors, incorporated by reference to Exhibit 4.1 to Akorn, Inc.’s report on Form 8-K filed on August 24, 2004.

(4.11)		Form of Common Stock Purchase Warrant between Akorn, Inc. and certain investors, incorporated by reference to Exhibit 4.2 to Akorn, Inc.’s report on Form 8-K filed on August 24, 2004.

(4.12)		Warrant Purchase and Registration Agreement dated June 18, 2003 between Akorn Inc. and AEG Partners LLC, incorporated by reference to Exhibit 4.1 to Akorn, Inc.’s report on Form 8-K filed on August 27, 2004.

(4.13)		Stock Registration Rights Agreement dated November 15, 1990 between Akorn, Inc. and The John N. Kapoor Trust dated 9/20/89, incorporated by reference to Exhibit 4.12 to Akorn, Inc.’s Registration Statement on Form S-1 filed on September 21, 2004.


Exhibit No.		Description
(4.14)		Stock Purchase Agreement dated November 15, 1990 between Akorn, Inc. and The John N. Kapoor Trust dated 9/20/89, incorporated by reference to Exhibit 4.13 to Akorn, Inc.’s Registration Statement on Form S-1 filed on September 21, 2004.

(4.15)		Form of Securities Purchase Agreement dated March 1, 2006 between Akorn, Inc. and certain investors, incorporated by reference to Exhibit 4.1 to Akorn Inc.’s report on Form 8-K filed March 7, 2006.

(4.16)		Form of Warrant issued in connection with the Securities Purchase Agreement dated March 1, 2006, incorporated by reference to Exhibit 4.2 to Akorn, Inc.’s report on Form 8-K filed on March 7, 2006. (All warrants are dated March 8, 2006. Please see Exhibit 99.1 of Akorn, Inc.’s report on Form 8-K filed March 14, 2006, which is hereby incorporated by reference, for a schedule setting forth the other material details for each of the warrants.)

(31.1)*		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934

(31.2)*		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934

(32.1)*		Certification of Chief Executive Officer pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002

(32.2)*		Certification of Chief Financial Officer pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002


	Page
PART I. FINANCIAL INFORMATION
ITEM 1. Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets-June 30, 2006 and December 31, 2005		3
Condensed Consolidated Statements of Operations-Three and six months ended June 30, 2006 and 2005		4
Condensed Consolidated Statement of Shareholders’ Equity-Six months ended June 30, 2006 and 2005		5
Condensed Consolidated Statements of Cash Flows-Six months ended June 30, 2006 and 2005		6
Notes to Condensed Consolidated Financial Statements		7
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		16
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk		19
ITEM 4. Controls and Procedures		19
PART II. OTHER INFORMATION
ITEM 1. Legal Proceedings		19
ITEM 1A. Risk Factors		19
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds		20
ITEM 3. Defaults Upon Senior Securities		20
ITEM 4. Submission of Matters to a Vote of Security Holders		21
ITEM 5. Other Information		21
ITEM 6. Exhibits		22


Nominee	Votes “For”		Votes “Withheld”
John N. Kapoor, Ph.D.		66,615,009		1,618,317
Arthur S. Przybyl		66,613,666		1,619,660
Jerry N. Ellis		68,159,345		73,981
Ronald M. Johnson		66,552,508		1,680,818
Jerry I. Treppel		68,098,330		134,996


	AKORN, INC.
	/s/ JEFFREY A. WHITNELL
	Jeffrey A. Whitnell
	Sr. Vice President, Chief Financial Officer (Duly Authorized and Principal Financial Officer)


		/s/ ARTHUR S. PRZYBYL

		Arthur S. Przybyl
		Chief Executive Officer


		/s/ JEFFREY A. WHITNELL

		Jeffrey A. Whitnell
		Chief Financial Officer


		/s/ ARTHUR S. PRZYBYL

		Arthur S. Przybyl
		Chief Executive Officer


		/s/ JEFFREY A. WHITNELL

		Jeffrey A. Whitnell
		Chief Financial Officer